5-Amino-1MQ: A Literature Course in Six Modules

This course organises the published literature that surrounds 5-Amino-1MQ into six modules: what the compound is, the mechanism researchers describe, the outcomes reported study by study, what has been published about adverse events, what pharmacokinetic data exist, and the regulatory picture. It closes with an explicit list of what the studies did not test. Every module ends with a limits-of-the-evidence note, because the single most important feature of this literature is how much of it examines the enzyme target rather than this specific molecule in humans. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision about a health condition or any substance.

Module 1 — What 5-Amino-1MQ Is and How It Has Been Studied

5-Amino-1MQ is the common shorthand for 5-amino-1-methylquinolinium, a small permanently charged quinolinium salt. The word "amino" in the name refers to an amine functional group on the ring system, not to a chain of amino acids, so the compound is not a peptide in any chemical sense even though it is frequently discussed alongside peptides in consumer forums. Structurally it is described as a nicotinamide-mimetic — a molecule shaped to occupy the substrate pocket of an enzyme that normally processes nicotinamide.

That enzyme is nicotinamide N-methyltransferase (NNMT). A 2024 review in Archives of Pharmacal Research traced NNMT from its metabolic pathways to its status as a therapeutic target and surveyed the inhibitor chemistry that has been developed around it (PMID 39604638). Interest in NNMT as a metabolic target accelerated after a 2014 Nature paper in which researchers reported that NNMT knockdown protected mice against diet-induced obesity (PMID 24717514).

How the literature is structured

Work in this field falls into a small number of experimental categories, and it helps to keep them separate when reading claims about "5-Amino-1MQ research":

• Genetic loss-of-function — knockdown or knockout of NNMT in cells or animals, as in the diet-induced obesity study (PMID 24717514).
• Gain-of-function and expression mapping — studies showing where NNMT is elevated and what that associates with, such as the report that NNMT promoted M2 macrophage polarisation and myeloid-derived suppressor cell conversion in gallbladder carcinoma (PMID 36633260).
• Pharmacological inhibition — small-molecule inhibition of NNMT in a disease model, for example the 2025 report that NNMT inhibition improved limb function in experimental peripheral artery disease (PMID 41108586).
• Reviews and descriptive omics — syntheses such as the NNMT review (PMID 39604638) and tissue-level surveys, including a spatial proteomics study that catalogued aging-associated alterations in the renal tubulointerstitium (PMID 41062932).

Limits of the evidence (Module 1)

None of the verified papers summarised on this page is a human clinical trial of 5-Amino-1MQ. Findings about NNMT knockdown or about unnamed NNMT inhibitors do not automatically transfer to one named compound, and results obtained in mice, tumour tissue or cell culture describe those systems only.

Module 2 — Mechanism as Described in the Literature

The mechanistic story begins with methyl-group chemistry. NNMT transfers a methyl group from S-adenosylmethionine onto nicotinamide, producing 1-methylnicotinamide, and the 2024 review positioned this reaction at the junction of methyl-donor availability and NAD-related metabolic pathways (PMID 39604638). Because nicotinamide is also a salvage substrate for NAD synthesis, researchers have framed high NNMT activity as a drain on both methyl donors and nicotinamide supply — the conceptual reason inhibitors were designed at all.

Metabolic tissue

In the adipose and metabolic setting, the 2014 Nature study reported that knocking down NNMT protected mice from diet-induced obesity, tying the enzyme to energy handling in fat tissue (PMID 24717514). In liver, a 2020 Journal of Hepatology paper reported that endoplasmic-reticulum-stress-induced upregulation of NNMT contributed to the development of alcohol-related fatty liver, describing the enzyme as a stress-responsive participant rather than a static housekeeping gene (PMID 32389809).

Immune and tumour microenvironment

A 2025 Nature paper reported that NNMT inhibition in cancer-associated fibroblasts restored antitumour immunity, placing the enzyme inside the stromal compartment that shapes immune access to tumours (PMID 40702186). In gallbladder carcinoma, researchers reported that NNMT drove M2 macrophage polarisation through IL6 and myeloid-derived suppressor cell conversion through GM-CSF (PMID 36633260). A 2025 Molecular Cancer study reported that NNMT promoted acquired EGFR-TKI resistance in non-small-cell lung cancer through EGR1- and lactate-mediated double positive feedback loops (PMID 40089784).

Adjacent metabolite literature

Related small-metabolite work is sometimes cited in the same conversations. A 2024 Circulation Research study reported that the microbial tryptophan metabolite indole-3-propionic acid protected against heart failure with preserved ejection fraction in its experimental model (PMID 38264909). That is a different molecule with a different target and is included here only to show how metabolite-level findings are frequently blended together in secondary summaries.

Limits of the evidence (Module 2)

Mechanism is inferred from knockdown, overexpression and inhibitor experiments in defined systems. A pathway that behaves one way in fibroblasts or hepatocytes may behave differently elsewhere, and none of these papers established that a particular mechanism operates at a particular exposure level in a living human being.

Module 3 — Reported Outcomes, Study by Study

The table below lists what each verified study modelled, what it measured and what it reported. No benefit for any person is implied; these are experimental results in the systems named.

Limits of the evidence (Module 3)

Two of these studies are oncology papers in which NNMT activity was unfavourable in tumour biology, while others target the enzyme for metabolic or vascular endpoints. That is not a contradiction, but it does mean no single directional summary — "NNMT inhibition is good" — is supported. Endpoints such as limb function in an animal model or immune infiltration in a tumour model are not the same as symptom, body-composition or longevity outcomes in people, and no verified paper here reports the latter.

Module 4 — 5-Amino-1MQ Side Effects: What Studies Report

The most accurate statement the verified literature supports is this: none of these papers published an adverse-event table, tolerability assessment or safety monitoring dataset for 5-Amino-1MQ in humans. There is no reported list of side effects to summarise, because no indexed human study in this set collected one. That absence is a gap in knowledge, not a finding of safety, and it is the reverse of what a tolerability profile looks like when one exists.

What the literature does provide is context that researchers themselves treat as a caution. The 2024 review of NNMT discussed the enzyme's breadth across metabolic pathways while framing it as a therapeutic target still under development (PMID 39604638). Oncology studies reported that NNMT activity promoted immunosuppressive macrophage and MDSC phenotypes in gallbladder carcinoma (PMID 36633260) and drove EGFR-TKI resistance in lung cancer models (PMID 40089784), while another study reported that inhibiting NNMT in cancer-associated fibroblasts changed antitumour immunity (PMID 40702186). Taken together, researchers describe an enzyme whose activity intersects immune signalling, methyl-donor economics and tumour-stroma crosstalk — domains in which any systemic modulation would be expected to require monitoring, not assumed to be inert.

The liver literature adds a further note: the 2020 study reported that NNMT was upregulated as part of an ER-stress response during alcohol-related fatty liver development, meaning its expression tracked with a pathological state rather than being fixed (PMID 32389809). Baseline enzyme activity therefore varies by tissue and condition in these reports.

Limits of the evidence (Module 4)

No verified paper here defines a no-observed-adverse-effect level, an organ-toxicity screen, a drug-interaction profile or any human safety signal for 5-Amino-1MQ. Anecdotal reports circulating outside the peer-reviewed literature are not evidence and are not reproduced on this page.

Module 5 — Pharmacokinetics, Where Data Exist

For 5-Amino-1MQ specifically, the verified literature indexed here contains no absorption, distribution, metabolism or excretion dataset, no half-life, no bioavailability figure and no human exposure measurement. Claims about oral versus injectable equivalence, duration of action, or accumulation cannot be sourced from these papers, so this page states no dose and no schedule.

What the literature does illustrate is the shape of a pharmacokinetic and pharmacodynamic package when one has been assembled. A 2024 paper on the dual GCGR/GLP-1R agonist survodutide described biomarker work and pharmacological profiling used for clinical candidate selection, showing the level of characterisation expected before a molecule advances (PMID 38560764). Nothing comparable appears in the verified set for 5-Amino-1MQ.

On the biomarker side, the NNMT review described 1-methylnicotinamide as the methylated product of the NNMT reaction, which is why researchers discuss product measurement as a way to read enzyme activity (PMID 39604638). Analytical proteomics work shows how enzyme and substrate landscapes are catalogued in tissue — for instance the study that mapped the rheumatoid-arthritis-associated citrullinome as a systematic enzyme-product inventory (PMID 29628436) and the spatial proteomics survey of the aging renal tubulointerstitium (PMID 41062932).

Limits of the evidence (Module 5)

Target-engagement biomarkers are not pharmacokinetics. Without dosing, exposure and clearance data in humans, the relationship between any administered quantity of 5-Amino-1MQ and any measured biological change remains uncharacterised in this literature.

Module 6 — Regulatory Status, Stated Factually

5-Amino-1MQ is not an approved medicine. No finished drug product containing 5-Amino-1MQ has been approved by the U.S. Food and Drug Administration or, to the best of the published record summarised here, by the European Medicines Agency. Material bearing this name is typically labelled research use only (RUO), a designation meaning the substance is intended for laboratory investigation and is not manufactured, tested or labelled for diagnostic or therapeutic use in people.

In the United States, pharmacy compounding of a bulk drug substance under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally depends on that substance being a component of an FDA-approved drug, being the subject of a USP or NF monograph, or appearing on FDA's relevant bulk drug substances lists. A substance meeting none of those conditions does not become eligible simply because research literature exists about its target. The contrast with a conventional development programme is visible in the survodutide candidate-selection paper, where biomarker and pharmacological profiling were reported as part of formal clinical candidate selection (PMID 38560764).

Regulatory status also differs by country, and RUO chemicals sold for laboratory work are governed by different rules than medicines. This section is general information, not legal advice.

Limits of the evidence (Module 6)

Regulatory lists and monograph status change over time, and this page does not track any single jurisdiction's current filings. Nothing in the verified scientific papers cited here speaks to legality, quality, purity or identity of any material.

What the Studies Did Not Test

Reading the verified literature as a whole, the following were not examined in the papers cited on this page:

1. Humans taking 5-Amino-1MQ. No clinical trial of the compound appears in this set; the metabolic anchor study was a mouse knockdown experiment (PMID 24717514).
2. Dose-response. No verified paper here reports a human dose, route, frequency or duration for 5-Amino-1MQ.
3. Fat loss or body-composition outcomes in people. Weight-related findings in this set were reported in diet-induced obesity models in mice (PMID 24717514).
4. Long-term safety. No chronic toxicology, carcinogenicity or reproductive study of the compound is included; the oncology papers instead describe NNMT's context-dependent roles in tumour biology (PMID 40089784).
5. Interactions. No drug–drug, supplement or NAD-precursor interaction study for 5-Amino-1MQ appears in the verified list.
6. Special populations. Pregnancy, paediatric, renal and hepatic-impairment populations were not studied for this compound, although liver NNMT biology itself was examined in an alcohol-related fatty liver model (PMID 32389809).
7. Comparative effectiveness. No head-to-head comparison against an approved therapy is present; the survodutide paper shows what a formal profiling programme reports instead (PMID 38560764).

The honest summary of this literature is that NNMT is an actively investigated enzyme with published preclinical evidence on both sides of the therapeutic ledger, and that 5-Amino-1MQ is a laboratory chemistry tool associated with that target rather than a characterised medicine. Anyone weighing information about it is reading a preclinical, target-level evidence base. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about health, medications or research compounds.

References

• Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Nature, 2014)
• NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity (Nature, 2025)
• Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease (Physiological Reports, 2025)
• Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma (Hepatology, 2023)
• NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer (Molecular Cancer, 2025)
• ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development (Journal of Hepatology, 2020)
• Exploring NNMT: from metabolic pathways to therapeutic targets (Archives of Pharmacal Research, 2024)
• The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection (Diabetes, Obesity & Metabolism, 2024)
• Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction (Circulation Research, 2024)
• Spatial proteomics to discover aging-associated alterations in the renal tubulointerstitium (Clinical Proteomics, 2025)
• Integrated Analysis of the Anoikis-Related Signature Identifies Rac Family Small GTPase 3 as a Novel Tumor-Promoter Gene in Hepatocellular Carcinoma (MedComm, 2025)
• The Rheumatoid Arthritis-Associated Citrullinome (Cell Chemical Biology, 2018)